Mandate

Vinge has acted as advisor to APG Asset Management in their investment in Areim Fund II

October 10, 2012

Vinge has acted as advisor to APG Asset Management in their investment in Areim Fund II, a real estate fund mainly focusing on office properties in larger Swedish cities. Areim Fund II has a target of commitments of SEK 2.5 billion upon final closing, which would give Areim Fund II around SEK 6-7 billion to invest.

APG has EUR 314 billion in assets under management (approximately 30% of the collective pension schemes in the Netherlands).

Vinge has about 50 lawyers focusing on private equity, of which approximately 12 are active within fund establishment (with competence within tax, corporate, M&A and finance law). Vinge has for several years been active in fund establishment and was e.g. the advisor to the first fund established in the form of a limited liability company in Sweden. Vinge has since then been involved in the majority of fund establishments in this form.

Partner in charge was Christina Kokko assisted by project manager Johan Steen and associate Jonatan Lund Kirkhoff.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026